

MNG Exome Test Request Form

5424 Glenridge Drive NE Atlanta, GA	A 30342 USA	phone: 844.664.8	8378 fax: 678.2	25.0212 mnglabs.com	
	roband and S	pecimen Inform	nation		
Patient	Patient			☐ Male ☐ Female	
Last Name	First Name			Specimen Type	
Patient ID #	Date of Birth [MM/DD/YYYY]			☐ Whole Blood ☐ Buccal Swab	
Diamasia/ICD 40	Collection Date			☐ DNA:	
Diagnosis/ICD-10	[MM/DD/YYYY]			☐ Tissue:	
Referring Physician Infor	1,			Results	
	PI#		Recipient	Results	
*	Required)		Name		
Facility/ Si	gnature		Facility	Phone	
Organization					
Facility Address City, State, Zip Code Same as billing			□Fax		
Report Delivery	Phone				
□Fax □Email	1 110110		□Email		
Billing Information			Recipient		
If you MICT include never contact name 9 details helevy Dayment must			Name		
Self-Pay? Yes received in full prior to testing. Facility Contact			Facility	Phone	
Name	,				
Billing Address			□Fax		
			 		
City, State, Zip Code			□Email		
Phone Fax	Email				
MNG Exome Sequencing			Add-	On Testing	
 Includes detection of copy number variants (CNVs) and 		Mitochondria	I DNA (no cost)	9	
 Testing will not begin until all samples to be analyze Consent forms and clinical information must be included 		☐ mtDNA S	Sequencing + Delet	ion	
	1				
☐ Trio Sequencing			The following assays are available as add-on tests. To add any of these to your order, please select from the following menu. List or contracted pricing		
☐ Duo Sequencing		will apply.			
☐ Proband Only Sequencing		Repeat Expan	Repeat Expansions (select one or more)		
Additional Comparator					
MNG STAT Exome™ Sequencing			☐ Huntington's disease (HTT) ☐ C9orf72 ☐ Friedreich's Ataxia (FRDA) ☐ Myotonic Dystrophy 1		
Rapid testing - results in 10-14 days		_			
 Testing will not begin until all samples to be analyzed are received 		- Spiriocei	Spinocerebellar Ataxia (SCAs) Myotonic Dystrophy 2		
Consent forms and clinical information must be include	a .	RNA Seque	RNA Sequencing (select one)		
Trio Sequencing			IMPORTANT: Please contact MNG prior to ordering RNA sequencing to		
☐ Duo Sequencing		avoid delays i	avoid delays in sample processing. An additional sample is required.		
☐ Proband Only Sequencing☐ Additional Comparator		☐ MNG Tra	nscriptome	Gene-Specific RNA Sequencing	
		1 416 6			
Last Name	First Name	nber 1 Information	on		
Lastivame	First Name			☐ Male ☐ Female	
Relationship	Date of Birth			Specimen Type	
to Proband	[MM/DD/YYYY]		☐ Whole Blood ☐ Buccal Swab		
Affected? Include Clinical Info	Collection Date		□ DNA:		
☐ Yes ☐ No ☐ Unsure	[MM/DD/YYYY]			Tissue:	
		nber 2 Informati	on		
Last Name	First Name			☐ Male ☐ Female	
Deletion skip	Date of Dieth			Specimen Type	
Relationship to Proband	Date of Birth [MM/DD/YYYY]			☐ Whole Blood ☐ Buccal Swab	
Affected? Include Clinical Info	Collection Date			☐ DNA:	
☐ Yes ☐ No ☐ Unsure	[MM/DD/YYYY]			Tissue:	
Additional Comparator Information					
Last Name First Name				☐ Male ☐ Female	
	1			Specimen Type	
Relationship	Date of Birth			☐ Whole Blood ☐ Buccal Swab	
to Proband Affected? Include Clinical Info	[MM/DD/YYYY]			DNA:	
☐ Yes ☐ No ☐ Unsure	Collection Date [MM/DD/YYYY]			☐ Tissue:	



Clinical Information Form

5424 Glenridge Drive NE | Atlanta, GA 30342 USA | phone: 844.664.8378 | fax: 678.225.0212 | mnglabs.com

Patient Name _ DOB Clinical (Check All That Apply) ☐ Retinitis Pigmentosa Hearing **Neuronal Migration** ☐ Optic Atrophy Eye ☐ Sensorineural ☐ Stickler ☐ Usher ☐ Joubert ☐ Other ☐ Stroke ☐ Other ☐ Intellectual Disability (ID) ☐ Syndromic ID Cognitive/Neurobehavioral ■ Nonsyndromic ID ☐ Autism Dementia ☐ Ataxia ☐ Episodic Ataxia ☐ Dystonia ☐ Chorea/Athetosis ☐ Parkinson Disease ☐ L-Dopa Response **Movement Disorders Connective Tissue & Bone** Epilepsy ☐ Myoclonic ☐ Other **Spasticity** ☐ Absence ☐ Tonic Clonic ☐ Spastic Paraplegia ☐ Other ☐ Ehlers Danlos ☐ Marfan ■ Aneurysms ☐ Epileptic Encephalopathy ☐ Spastic Quadriplegia ☐ Other **Nerve/Anterior Horn Cell** Neuromuscular Distal ☐ Proximal ■ Muscle Atrophy ☐ Contractures ☐ Neurofibromas ☐ Charcot-Marie-Tooth ☐ Sensory Rhabdomyolysis ■ Malignant Hyperthermia ☐ Arthrogryposis ☐ Autonomic ☐ Pain ☐ Motor ☐ Nerve Conduction ☐ Periodic Paralysis ☐ Statin Use ■ Myasthenia ☐ Other **Arrhythmias Congenital Heart Defects** Cardiomyopathy **Endocrine** ☐ Ventricular Tachycardia
☐ Brugada ☐ Heterotaxy ☐ Dilated ☐ Hypertrophic ☐ Other ☐ Hypothyroidism ☐ Long or Short QT ☐ Conduction Defect ■ Noncompaction ☐ Other ☐ Diabetes Mellitus Imaging (Check All That Apply) Brain MRI **EEG (Describe Findings) EMG/NVC** (Describe Findings) Leigh Disease ☐ Basal Ganglia Calcification ☐ Stroke ☐ Cerebellar Atrophy ☐ Abnormal Myelin (describe) Laboratory Metabolic (Describe Findings) **Genetic (Describe Findings)** ☐ Chromosomal Microarray ■ Deletion/Insertion Testing ☐ Other (comment) **CPK** Maximum ___ Minimum _ **Family History** Ethnicity (please check) ☐ Caucasian ☐ Sephardic Jewish ☐ African American (or Black) ☐ Asian Hispanic ☐ Ashkenazi Jewish ☐ Native American (or American Indian) Other: **Affected Maternal Lineage Affected Paternal Lineage Siblings** Relationship to Proband Relationship to Proband Number (specify gender) Symptoms Symptoms Healthy/Affected **Additional Comments**



Informed Consent Whole Exome & Whole Genome Sequencing

5424 Glenridge Drive NE | Atlanta, GA 30342 USA | phone: 844.664.8378 | fax: 678.225.0212 | mnglabs.com

Notice to Health Care Practitioner:

This document is a consent form for clinical whole exome or whole genome sequencing. Currently, the laboratory will only accept whole exome and whole genome test requests after the patient/parent or legal guardian/next of kin has received genetic counseling from a Healthcare Provider with experience in counseling patients for such a test. Please be aware of any applicable state laws in regards to counseling needs related to the current condition, the possibilities of detecting unsuspected conditions as well as other issues related to health insurance, and possible effects on life insurance. Please explain this consent to the patient, or authorized representative/guardian, and obtain an informed consent. Please explain the list of potential incidental findings that may be reported to the patient.

Consent for WES and WGS Testing

All of the above has been explained to me, to my satisfaction, and my signature below attests to the same. I understand that this is a voluntary test, and I have had the opportunity to ask questions about alternative testing.

Whole Exome or Whol	Name of Family Member: _	
Prohand Name:		Signature:
Proband DOB:		Relationship to Proband:
	gnature if person being tested is a minor)	Name of Family Member: _ Signature:
Health Care Provider Obtaining Consent: Print Name:		Relationship to Proband:
Signature:		Name of Family Member: _
NPI#:		Signature:
I have provided genetic counseling and have explained the risks, benefits, and limitations of WES testing to the patient/parent/guardian.		Relationship to Proband:

Additional Consent

What are incidental findings?

During testing, disease causing variants can be identified that are not related to the patient's condition for which the testing was done. These are referred to as "Incidental Findings" and indicate the presence of previously undiagnosed, potentially serious conditions that can be prevented or treated if diagnosed. A list of such conditions based on the recommendation of the American College of Medical Genetics (ACMG) is provided on the ACMG website. Please state whether you want to be informed about incidental findings in relation to the conditions listed.

How long are WES and WGS results kept in the testing lab?

The laboratory may keep the identified WES/WGS raw data in the lab indefinitely. This helps us improve our diagnostic capabilities and will help others with similar conditions. To advance the understanding of genetic disorders, your results might be analyzed and published in scientific articles in a de-identified manner consistent with HIPAA guidelines.

What will happen to my DNA sample?

No additional tests will be performed on these samples, without specific, signed authorization by the individual(s). After 60 days, unless consent is given, the sample will be destroyed.

Consent of family members submitting a sample for evaluation of patient's results:

I understand that I am submitting my sample to help evaluate the results obtained on the person being tested, and that results obtained from my sample will be used solely for this purpose. I will NOT be informed of any test results on my sample. If I request any test results, I will have to be tested separately.

Relationship to Proband:	Date:			
Name of Family Member:				
Signature:				
Relationship	Date:			
to Proband:	Date.			
Name of Family Member:				
Signature:				
Relationship	Date:			
to Proband:	Date.			
Incidental Findings Consent (initial)				
2. Raw Data Storage Consent (initial)				
We agree that our WES/WGS data	We agree that our WES/WGS data			
may be stored indefinitely	may be used for scientific publication in a de-identified manner			
Proband	Proband			
Mother	Mother			
Father	Father			
Other	Other			
3. DNA Sample Retention Consent Please keep my DNA used for WGS/WES for future testing should I desire such testing or if I want to participate in research in the future. I understand no additional genetic tests will be performed without my specific consent/ instructions, but my DNA may be used for quality control purposes. I understand that there is no guarantee of availability of my DNA after 60 days. Proband Mother Father Other				

Informed Consent for Patients and/or Legal Guardians:

What is whole exome sequencing (WES) and whole genome sequencing (WGS)?

Whole exome sequencing (WES) and whole genome sequencing (WGS) are genetic tests. They are performed on DNA extracted from 3 ml of blood or other acceptable tissue type. Their purpose is to identify a heritable cause of a disorder. WES examines the "exome" or coding regions of DNA, the most important information containing segment of the genome, and will often identify the cause of disease. WGS examines all of the DNA in the human genetic code including coding and non-coding regions.

The sensitivity of both tests is improved if blood is submitted from biological parents or siblings of the patient. The goal of both tests is to identify the genetic cause of the disease for which the patient is presenting. For this reason, it is crucial that a detailed description of the clinical symptoms of the patient and other affected family members is provided. Results will only be reported on the patient. Because WES and WGS results have potential consequences for the patient's family, we recommend that the consenting and ordering process be performed with the assistance of a genetic counselor and/or the ordering physician.



Informed Consent Whole Exome & Whole Genome Sequencing

5424 Glenridge Drive NE | Atlanta, GA 30342 USA | phone: 844.664.8378 | fax: 678.225.0212 | mnglabs.com

What kind of results are reported?

- 1. Positive: Variant(s) have been identified that are known to cause the disease symptoms based on the available scientific evidence at the time of testing.
- 2. Indeterminate: Variant(s) have been identified that are likely to cause the disease symptoms based on the available scientific evidence at the time of testing, but there is a lack of definitive scientific evidence available to prove it.
- 3. Negative: No variant has been identified that is known or likely to cause the disease symptoms based on the available scientific evidence at the time of testing.

What implications do positive and negative results have?

When WES/WGS detects known disease causing variants, the test result is highly accurate. A positive result will help your clinician to better predict the course of the condition and provide you with treatment options, if they exist. The results will also help determine the risk of recurrence of the condition in other children. An indeterminate result will point to a probable cause of a condition, but you may wish to consult a genetic counselor or your physician and undergo further independent testing to confirm or rule out the proposed role. A negative result does not indicate the absence of a genetic cause and will not change the clinical diagnosis.

Are there limitations to WES and WGS testing?

WES and WGS are screening tests. There is a possibility a genetic variant caused a condition that is not identified by the WES/WGS tests either because of the technical limitations of the assays, or because of incomplete understanding of the significance of variants detected. Although WES/WGS testing is highly accurate, the interpretation of the report is based on current medical knowledge, which is not complete.

- 1. WES may not be able to detect genetic disorders that are caused by expansion of repetitive regions of the genome. One example is Fragile X Syndrome. If one of these types of conditions is suspected, your physician should order the appropriate test.
- 2. Not all regions in the human genome can be sequenced due to limitations in technology, so some variants in such regions might go undetected with WGS methodologies.

Are there results that will not be reported?

- 1. Samples from the patient's relatives may be used to help diagnose the patient's condition, but results for these relatives will not be reported independently. They will only be referred to in the report for the patient if they are directly relevant to the patient's condition. However, the patient's genetic results may have implications for their relatives, and it is important that these implications are discussed with a genetic counselor.
- 2. Variations in genes that affect susceptibility to a condition, but do not cause the person to develop the condition, will not be reported.
- 3. Carrier status for recessive disorders: Most people carry variants that are not disease causing but could become disease causing if that person had children with someone who was healthy but had the same variant. This is referred to as being a "carrier" for a disease. This test is not intended for determining carrier status. If you are concerned about carrier status for conditions that might run in your family, you should get tested separately for carrier status. You should discuss these implications with your genetic counselor.
- Single heterozygous pathogenic/likely pathogenic variants in genes associated with recessive disorders that have potential overlap with a patient's clinical presentation (as provided to our laboratory) will be reported since we cannot definitively exclude that an undetected second variant in trans may be present.
- Single heterozygous variants of uncertain significance in genes associated with recessive disorders that have potential overlap with a patient's clinical
 presentation (as provided to our laboratory) will be reported at the discretion of the laboratory director.
- Single heterozygous variants in genes associated with recessive disorders that do not have overlap with the patient's clinical presentation (as provided to our laboratory) will not be reported.

Who will have access to the results?

Test results are maintained electronically by the laboratory. The results are provided to the ordering physician and/or healthcare facility that ordered the test. Results may also be made available to individuals/organizations with a legal right of access under applicable Federal and/or State law, or as authorized by the patient or the patient's representative. Patient privacy is of utmost concern to us, and as a CAP certified facility we are prepared to safeguard Protected Health Information.

What are the risks of testing?

- 1. Non-paternity (when the reported father of the child is not the biological father) or half sibling-ships (when siblings do not share the same father AND mother) would be detected. We do not report these findings unless they have direct clinical significance.
- 2. Genetic non-discrimination law prevents insurance companies from using your genetic information to deny health insurance coverage, but the law does not cover life insurance, disability insurance or long-term care insurance. The detection of an incidental condition may affect your future ability to buy these forms of insurance or get the best insurance rates. Please be aware of any applicable State laws and applicable terms of any active insurance policies in regards to consent and the release of these results to insurance companies.
- 3. WES/WGS may identify serious and/or untreatable genetic conditions. It can result in unexpected psychological trauma, both for you and your family. The detection of such a condition or conditions could also affect the health or healthcare needs of your siblings, children, or other close relatives.
- 4. Although WES/WGS is highly accurate, the interpretation of the report is based on current medical knowledge, which is not complete. We do not report out changes in interpretation of variants automatically, but we do have mechanisms to issue an updated report if requested by the patient's physician.